Advanced stage gastric cancer and neoadjuvant chemotherapy: our experience in surgical resectability

Ann Ital Chir. 2013 Nov-Dec;84(6):623-9.

Abstract

Background: In the last years the incidence of gastric cancer is changed as the complementary therapy to surgical treatment especially about the advanced stage gastric cancer.

Materials and methods: We have analyzed the patients treated at Unit of General Surgery and Organ Transplantation of University Hospital of Parma from 1/1/2009 to 30/9/2012. The cases surgically treated after neoadiuvant therapy were compared to patients not treated with neoadiuvant therapy.The choice to neoadiuvant therapy was decided on locally advanced disease and low comorbidity.

Results: The cases surgically treated were 93, in 9 cases were treated with neoadiuvant therapy. The histotype in neoadiuvant cases was an intestinale type 3 cases, a diffuse type 3 cases and no classificable sec. Lauren 3 cases. The average of number of lymphnodes removed was 22.5 in total gastrectomy and 15.7 nodes in partial gastrectomy. On RECIST criteria the response to neoadiuvant chemotherapy were in 2 cases a partial response and in the others 7 cases the disease remained stable.

Conclusion: In our experience as in literature, the neoadiuvant therapy can reduce staging, increases the R0 resection, should proposed in young patients with low comorbidity.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Chemotherapy, Adjuvant
  • Female
  • Gastrectomy*
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery*